After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

Cancer cells frequently express PD-L1 protein to evade immune attack. When PD-L1 on a tumor cell surface binds to PD-1 on a T cell, the T cell becomes inactivated and loses its ability to destroy the ...

As described in the abstract, investigators will present first evidence that A2B receptor inhibition reduces the adenosine-mediated increase in PD-L1 in a human epithelioid mesothelioma cell line, ...

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

Takeda has partnered with China's Innovent Biologics for a pair of late-stage cancer therapies, in a deal that includes an ...

Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, >90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and ...

Poster presented today in Boston shows direct anti-tumor activity in mesothelioma models, reduced tumor PD-L1 alongside decreased pCREB, and strong TT-4 monotherapy activity with added benefit in anti ...

Genprex (($GNPX)) announced an update on their ongoing clinical study. Genprex (GNPX) is conducting a clinical study titled ‘A Phase 1/2 Clinical ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...